Study tiny RNA changes in triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies patterns of microRNA (tiny gene-regulating molecules) in women with triple-negative breast cancer. By comparing these microRNA profiles, the study hopes to better understand the disease and potentially guide future treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 to 70
- You have a breast tumor confirmed as cancer that is “triple-negative” on a special lab test (IHC)
- Your tumor is large enough for a needle biopsy (at least 2 cm) and is reachable by ultrasound or exam
- You have not had chemotherapy for this breast cancer, and you are in stage IIA to IIIC
- You can do the study activities and are generally well (ECOG 0 to 1)
- Your key blood, liver, and kidney tests are in acceptable ranges, and your heart ultrasound shows normal pumping (left ejection fraction ≥55%)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a standard chemotherapy treatment for Nigerian women with triple-negative breast cancer that has not spread widely. It aims to see how well the treatment works and how safe it is.
This study tests whether a new approach using a genetic test can guide treatment for low-risk triple-negative breast cancer. It aims to help patients avoid unnecessary chemotherapy while keeping the cancer from coming back.
This trial tests a new drug called LBL-024, either alone or with other medicines, for people with triple negative breast cancer. It aims to see if the drug can shrink tumors and how safe it is.
This Phase 3 study tests whether a special form of docetaxel (a chemotherapy drug) works better and is safe for people with triple-negative breast cancer that has spread or grown locally. You may be eligible if your cancer is triple-negative and you have measurable disease that can be tracked on scans, along with adequate organ and heart function.
This trial tests whether using blood tests and imaging during chemotherapy and immunotherapy can help guide treatment for early-stage triple-negative breast cancer. It aims to improve outcomes by adjusting treatment based on how the cancer responds.
This trial tests whether using tumor “genetics” (information from your biopsy) to guide radiation planning can improve treatment for triple-negative breast cancer. It may help by aiming radiation more precisely while still using standard approaches where needed.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.